The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

with its lead antibiotic candidate, ibezapolstat, preparing to advance to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). The Company today announced updates ...

She also said this could lead to other issues, like resistance to the antibiotic and increasing your risk of C. diff. “People ...

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile ...

The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.

In the largest study of its kind in the UK, a research team from Queen’s University Belfast have discovered a new way to ...

Your digestive system does more than just process food—it’s home to trillions of tiny organisms, mostly bacteria, that play a ...

Fintel reports that on December 11, 2024, Wells Fargo initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...